This piece in CanadianSME Small Business Magazine features Peter Sampson of the Agora Open Science Trust, who leads a project using open science to drive the development of an affordable treatment for Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer. The project recently reached an important milestone for open science drug discovery, nominating a lead development candidate in their M4K Pharma program. This major milestone reflects the strength of collaborative, open science-driven research and highlights the meaningful progress supported through our Developing Medicines through Open Science (DMOS) program. In Peter’s own words:
“Conscience’s DMOS program has strengthened these collaborations by providing dedicated funding at a critical inflection point, as we transition from drug discovery to drug development. Advancing our lead molecule toward human clinical trials is an expensive and resource-intensive process, with few funding mechanisms available to support the IND-enabling studies required for regulatory approval. DMOS support helps de-risk the program by providing the resources necessary to navigate these regulatory requirements and move the project forward effectively.”
Read the full interview here »
